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In this issue ofCancer Cell, Zhang et al. reports that the iron-dependent 2-oxoglutarate dioxygenase or prolyl
hydroxylase EglN2 inducesCyclin D1 levels, egging on breast tumorigenesis. Their observations through loss
of function studies suggest the potential for drug-like molecules inhibiting EglN to serve as new cancer ther-
apeutics.EglN2 (also known as PHD1) is among
three known EglNs, with EglN1 (PHD2)
being key to the hydroxylation and degra-
dation of the hypoxia inducible factor 1a
(HIF-1a) (Berra et al., 2006; Epstein
et al., 2001; Kaelin and Ratcliffe, 2008).
Although the direct substrates for hydrox-
ylation by EglN2 and EglN3 are not well
understood, Zhang et al. document that
EglN2 activity positively influences the
level of Cyclin D1, independent of HIF,
in a series of in vitro experiments and
in genetically engineered mice (Zhang
et al., 2009). The authors linked EglN2 to
Cyclin D1 in breast tumorigenesis, partly
on the basis of their genetic connection
in Drosophila and the fact the EglN2 is
estrogen inducible, such that loss of
EglN2 activity diminishes breast tumori-
genesis that could be rescued by ectopic
Cyclin D1 expression.
Prolyl hydroxylases belong to the
superfamily of iron-dependent, 2-oxoglu-
tarate dioxygenases that use molecular
oxygen to hydroxylate specific prolyl resi-
dues of substrates whose functions may
be altered, or the hydroxylated substrates
are destined for degradation through
the proteasome (Kaelin and Ratcliffe,2008). EglNs have Km values for oxygen
that are higher than oxygen concentra-
tions inmammalian tissues, causing these
enzymes to be highly sensitive of oxygen
levels, which are naturally diminished in
areas of tissues distal from a blood vessel
or abruptly decreased by blockage of the
blood supply. With decreased oxygen
concentration, the EglNs are thought to
not only be inactivated by the lack of its
substrate oxygen but may also be
disabled by increased reactive oxygen
species (ROS) resulting from inefficient
mitochondrial respiration. ROS oxidizes
and inactivates the catalytic EglN ferrous
ion, resulting in loss of prolyl hydroxyl-
ation and stabilization of the EglNs’
substrates. Chief among the EglNs’
substrates is HIF-1a, which is a ubiquitous
transcription factor mediating cellular
genomic responses to hypoxia and a sub-
strate of EglN1 (Figure 1) (Semenza, 2007).
Zhang et al. noted on the basis of earlier
work by Frei and Edgar that the sole EglN,
Egl9, in Drosophila interacts genetically
with Cyclin D1 (Figure 1) (Frei and Edgar,
2004). Specifically, Frei and Edgar
observed that Cyclin D1 overexpression
in flies resulted in eye overgrowth, aCancer Cell 16phenotype that could be extinguished by
the concurrent loss of Egl9 function. By
examining EglN2/ mice, which are
grossly normal, Zhang et al. found that
Cyclin D1 mRNA and protein levels are
diminished in the mutant murine embry-
onic fibroblasts. They also document
hypoproliferation of mammary glands in
older EglN2 null mice reminiscent of the
more severe phenotype reported for the
Cyclin D1/ mice. These observations
in genetically engineered mice suggest
that loss of EglN2 function phenocopies
decreased Cyclin D1 activity in mammary
tissue. Intriguingly, although it is docu-
mented that hypoxia inhibits cell prolifera-
tion partly through the induction of p27
putatively downstream of HIF-1 in mam-
malian cells (Gardner et al., 2001), the
connection between EglN and Cyclin D1
in Drosophila and mice suggests a
possible alternative pathway to inhibit
cell proliferation when oxygen is lacking.
In this regard, EglN could play a direct
role in regulating the cell cycle by sup-
pressing a putative suppressor of Cyclin
D1 (Figure 1).
Cyclin D1 promotes the phosphoryla-
tion of the retinoblastoma protein (pRB),, November 3, 2009 ª2009 Elsevier Inc. 361
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Previewsby releasing E2F transcription
factors to stimulate cell prolif-
eration. The Cyclin D1 gene
is frequently amplified in
breast cancer and induced
by estrogen, and its loss of
function resulted in delayed
mammary tumorigenesis in
the mouse. EglN2, similar to
Cyclin D1, is induced by
estrogen, and EglN2 overex-
pression stimulates breast
cancer cell proliferation, sug-
gesting that estrogen could
stimulate breast cancer cell
proliferation through EglN2
and its downstream effectors
(Seth et al., 2002). The obser-
vation in Drosophila linking
Egl9 to Cyclin D1 suggests
that Cyclin D1 could be an
effector of estrogen-stimu-
lated breast cancer cell prolif-
eration downstream of EglN2.
In this regard, Zhang et al.
document that loss of EglN2 function
through the use of interference RNAs re-
sulted in diminished Cyclin D1 levels not
only in breast cancer cells but also in
several other cancer cell types, linking
EglN to Cyclin D1 in mammalian cells
(Figure 1). Although the work of Zhang
et al. did not delineate the EglN2 substrate
that in turn regulates Cyclin D1 levels,
their experiments document that EglN2
is likely to affect Cyclin D1 transcription,
suggesting that a substrate of EglN2
could be a transcriptional repressor. It is
notable, however, that ectopically ex-
pressed Cyclin D1 levels were also
affected by shRNA-mediated decreased
in EglN2 levels, leaving open the possi-
bility of an additional posttranscriptional
level of regulation.
The correlation and mechanistic con-
nection between EglN2 and Cyclin D1
breast tumorigenesis was delineated
by Zhang et al. through a series of exper-
iments that documents the correlation of
EglN2 mRNA levels with the estrogen
receptor (ER) status in human breast
cancers, such that EglN2 levels are high-
est in ER-positive tumors that contrast
with EglN1 levels, which are highest in
ER-negative, HER2-positive tumors. Gain
of EglN2 function via overexpression in
an estrogen-dependent breast cancer cell
line rendered it estrogen independent,
and conversely shRNA-mediated loss of
EglN2 function in this cell line resulted in
decreased Cyclin D1 expression and
diminished estrogen-stimulated prolifera-
tion. Furthermore, diminished EglN2
expression via inducible shRNA expres-
sion resulted in decreased in vivo tumor
xenograft growth, which was rescued by
ectopic, constitutive expression of Cyclin
D1. These observations collectively link
EglN2 to the regulation of Cyclin D1 in
estrogen-mediated breast tumorigenesis
(Figure 1).
The findings of Zhang et al. are
intriguing not only because they suggest
a link between the prolyl hydroxylase
EglN2, through a yet unknown EglN2
substrate, and Cyclin D1 in breast tumor-
genesis, but they also suggest that small
molecule inhibitors of EglNs could serve
as a new class of anticancer drugs (Fraisl
et al., 2009). Until better structural work
becomes available on EglNs and the
specificities of drug-like EglN inhibitors
are better established, the inhibition of
EglNs could affect the HIFs,
particularly because HIF-2a is
suggested to be downstream
of EglN2 (Aragones et al.,
2008). On the one hand, inhibi-
tion of EglN2 should diminish
Cyclin D1 levels, leading to
inhibition of tumorigenesis; on
theotherhand,cross-inhibition
of EglN1 by these drugs could
lead to the elevation of HIFs
that can potentiate tumorigen-
esis (Figure 1). Furthermore,
little is known about the chem-
istry and biology of EglN3,
prompting a cautionary note
about the useof EglN inhibitors
in human subjects, particularly
given that our understanding
of oxygen homeostasis in the
physiological setting of
normal tissue turnover and
repair is at best rudimentary
at this time.
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Figure 1. Schematic Diagrams Depicting the Links between EglNs
and Cyclin D1 in Drosophila and Mammals
As shown on the left, the diagram shows the genetic connection between
Cyclin D1, which is placed by epistasis upstream, and Egl 9, which is involved
in cell growth but not cell proliferation of the fly eye. As shown on the right, in
mammary tissue, EglN2 and Cyclin D1 are both responsive to estrogen with
EglN2 being placed upstream of an unknown prolyl hydroxylase substrate
(?) that regulates cell proliferation through Cyclin D1. The EglN1 substrate
HIF 1a is documented to play a pivotal role in tumor metabolic adaptation to
hypoxia and contributes to breast tumorigenesis.362 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc.
